Back to top
more

Allogene Therapeutics (ALLO)

(Delayed Data from NSDQ)

$2.72 USD

2.72
2,534,770

+0.17 (6.46%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.73 +0.01 (0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances

Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.

Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat

Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.

ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates

ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.

Allogene Therapeutics (ALLO) Reports Q1 Loss, Tops Revenue Estimates

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 47.92% and 56.54%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag

FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.

Allogene Therapeutics (ALLO) Up 3% Since Last Earnings Report: Can It Continue?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Gilead's (GILD) CAR T Cell Therapy Yescarta Gets FDA Nod for FL

Gilead's (GILD) CAR T-cell therapy gets a boost with the FDA approval of Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma.

Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances

Allogene (ALLO) reports no revenues for the fourth quarter of 2020.

Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod

The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.

Allogene Therapeutics (ALLO) Up 8.4% Since Last Earnings Report: Can It Continue?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses

Allogene (ALLO) reports no revenues for the third quarter of 2020.

Allogene Therapeutics (ALLO) Down 9.9% Since Last Earnings Report: Can It Rebound?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses

Allogene (ALLO) reports no revenues for the second quarter of 2020.

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Is (ALLO) Outperforming Other Medical Stocks This Year?

Has Allogene Therapeutics (ALLO) Outpaced Other Medical Stocks This Year?

Is (ALLO) Outperforming Other Medical Stocks This Year?

Why Is Allogene Therapeutics (ALLO) Up 40.6% Since Last Earnings Report?

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moving Average Crossover Alert: Allogene Therapeutics

Allogene Therapeutics, Inc. (ALLO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Is Allogene Therapeutics (ALLO) Outperforming Other Medical Stocks This Year?

Is (ALLO) Outperforming Other Medical Stocks This Year?

Implied Volatility Surging for Allogene (ALLO) Stock Options

Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.

Allogene Therapeutics (ALLO) in Focus: Stock Moves 6.6% Higher

Allogene Therapeutics (ALLO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Will Allogene Therapeutics Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Allogene Therapeutics

How Allogene (ALLO) Stock Stands Out in a Strong Industry

Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses

Allogene (ALLO) reports no revenues for the first quarter of 2020.

Kinjel Shah headshot

Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More

Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.